Journal
ONCOIMMUNOLOGY
Volume 2, Issue 7, Pages -Publisher
TAYLOR & FRANCIS INC
DOI: 10.4161/onci.24889
Keywords
B cells; FcRI; IL-10; IgG4; VEGF; antibody effector functions; cancer inflammation; immune escape; melanoma
Categories
Funding
- National Institute for Health Research (NIHR) Biomedical Research Centre based at Guy's and St Thomas' NHS Foundation Trust
- King's College London
- Cancer Research UK [C30122/A11527, C16736/A8371]
- Mary Dunhill Trust
- CR UK//NIHR in England/DoH for Scotland, Wales and Northern Ireland Experimental Cancer Medicine Centre
- CR UK/EPSRC/MRC/NIHR KCL/UCL Comprehensive Cancer Imaging Centre [C1519/A10331]
- Overseas Research Students Award Scheme
- Medical Research Council [MR/J006742/1] Funding Source: researchfish
Ask authors/readers for more resources
The role of B cells and antibodies in cancer is insufficiently understood but is receiving increasing attention. We have recently identified IgG4 as an antibody subclass elicited by melanoma-associated interleukin-10-driven inflammation. In this setting, IgG4 exhibit inefficient immunostimulatory capacity and block the cytotoxic activities of other antibodies. These previously unappreciated mechanisms of immune escape may constitute promising targets for the development of novel anticancer immunotherapies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
